摘要
Fas ligand (FasL) was first described functionally as an inducible cell surface molecule used by cytotoxic T cells to induce apoptotic cell death in tumor cells and activated lymphocytes. With the identification of Fas as the Ipr gene product, FasL became recognized as a molecule involved in down-regulation of the immune system. While FasL can be used to efficiently kill Fas-expressing tumor cells as well as activated T and B lymphocytes in vitro, attempts to use FasL therapeutically to treat cancer or to prevent
基金
This work was supported in part by USPHS-NIH SBIR grants AI-40394, AI-40607, and AI-47168.
